Geron Corporation's Telomerase Inhibitor Drug May Benefit Breast Cancer Patients Receiving Radiation Therapy

Published: Dec 19, 2006

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today reported that its telomerase inhibitor drug, GRN163L, may benefit breast cancer patients receiving radiation therapy, according to the results of a study published online in the International Journal of Radiation Oncology, Biology and Physics (www.redjournal.org/inpress).

Back to news